361 related articles for article (PubMed ID: 33393073)
1. Farnesoid X receptor: a potential therapeutic target in multiple organs.
Zhang C; Wang Z; Feng Q; Chen WD; Wang YD
Histol Histopathol; 2020 Dec; 35(12):1403-1414. PubMed ID: 33393073
[TBL] [Abstract][Full Text] [Related]
2. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
3. Update on FXR Biology: Promising Therapeutic Target?
Han CY
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30013008
[TBL] [Abstract][Full Text] [Related]
4. Progress and challenges of selective Farnesoid X Receptor modulation.
Massafra V; Pellicciari R; Gioiello A; van Mil SWC
Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
[TBL] [Abstract][Full Text] [Related]
5. FXR signaling in the enterohepatic system.
Matsubara T; Li F; Gonzalez FJ
Mol Cell Endocrinol; 2013 Apr; 368(1-2):17-29. PubMed ID: 22609541
[TBL] [Abstract][Full Text] [Related]
6. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
Sun L; Cai J; Gonzalez FJ
Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
[TBL] [Abstract][Full Text] [Related]
7. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
[TBL] [Abstract][Full Text] [Related]
8. Discovery of farnesoid X receptor and its role in bile acid metabolism.
Chiang JYL; Ferrell JM
Mol Cell Endocrinol; 2022 May; 548():111618. PubMed ID: 35283218
[TBL] [Abstract][Full Text] [Related]
9. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer.
Yin Y; Wang M; Gu W; Chen L
Biochem Pharmacol; 2021 Apr; 186():114430. PubMed ID: 33556338
[TBL] [Abstract][Full Text] [Related]
10. MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases.
Sonne DP
Eur J Endocrinol; 2021 May; 184(5):R193-R205. PubMed ID: 33630750
[TBL] [Abstract][Full Text] [Related]
11. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
[TBL] [Abstract][Full Text] [Related]
12. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
Chiang JYL; Ferrell JM
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling.
Wahlström A; Kovatcheva-Datchary P; Ståhlman M; Bäckhed F; Marschall HU
Dig Dis; 2017; 35(3):246-250. PubMed ID: 28249261
[TBL] [Abstract][Full Text] [Related]
15. The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: An old story, yet mesmerizing.
Liu T; Song X; Khan S; Li Y; Guo Z; Li C; Wang S; Dong W; Liu W; Wang B; Cao H
Int J Cancer; 2020 Apr; 146(7):1780-1790. PubMed ID: 31291465
[TBL] [Abstract][Full Text] [Related]
16. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
17. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
Zhou W; Anakk S
Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
[TBL] [Abstract][Full Text] [Related]
18. Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism.
Massafra V; van Mil SWC
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):45-59. PubMed ID: 28986309
[TBL] [Abstract][Full Text] [Related]
19. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
20. Bile Acid Physiology.
Di Ciaula A; Garruti G; Lunardi Baccetto R; Molina-Molina E; Bonfrate L; Wang DQ; Portincasa P
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s4-s14. PubMed ID: 29080336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
